100 related articles for article (PubMed ID: 31493625)
1. The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease.
Janssen JAMJL; Varewijck AJ; Brugts MP
Growth Horm IGF Res; 2019; 48-49():16-28. PubMed ID: 31493625
[TBL] [Abstract][Full Text] [Related]
2. Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling.
Varewijck AJ; Brugts MP; Frystyk J; Goudzwaard JA; Uitterlinden P; Waaijers AM; Feng Y; Dimitrov DS; Lamberts SW; Hofland LJ; Janssen JA
Mol Cell Endocrinol; 2013 Jan; 365(1):17-24. PubMed ID: 22982059
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor I: pros and cons of a bioassay.
Janssen JA
Horm Res Paediatr; 2011; 76 Suppl 1():106-10. PubMed ID: 21778760
[TBL] [Abstract][Full Text] [Related]
4. Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays.
Brugts MP; Ranke MB; Hofland LJ; van der Wansem K; Weber K; Frystyk J; Lamberts SW; Janssen JA
J Clin Endocrinol Metab; 2008 Jul; 93(7):2539-45. PubMed ID: 18397983
[TBL] [Abstract][Full Text] [Related]
5. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum.
Chen JW; Ledet T; Orskov H; Jessen N; Lund S; Whittaker J; De Meyts P; Larsen MB; Christiansen JS; Frystyk J
Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1149-55. PubMed ID: 12604504
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the GH/IGF-axis components: lessons from human studies.
Frystyk J
Domest Anim Endocrinol; 2012 Aug; 43(2):186-97. PubMed ID: 22153974
[TBL] [Abstract][Full Text] [Related]
7. Circulating bioactive and immunoreactive IGF-I remain stable in women, despite physical fitness improvements after 8 weeks of resistance, aerobic, and combined exercise training.
Nindl BC; Alemany JA; Tuckow AP; Rarick KR; Staab JS; Kraemer WJ; Maresh CM; Spiering BA; Hatfield DL; Flyvbjerg A; Frystyk J
J Appl Physiol (1985); 2010 Jul; 109(1):112-20. PubMed ID: 20395543
[TBL] [Abstract][Full Text] [Related]
8. Effects of Prednisolone on Serum and Tissue Fluid IGF-I Receptor Activation and Post-Receptor Signaling in Humans.
Ramshanker N; Aagaard M; Hjortebjerg R; Voss TS; Møller N; Jørgensen JOL; Jessen N; Bjerring P; Magnusson NE; Bjerre M; Oxvig C; Frystyk J
J Clin Endocrinol Metab; 2017 Nov; 102(11):4031-4040. PubMed ID: 28945869
[TBL] [Abstract][Full Text] [Related]
9. The effect of submaximal exercise on immuno- and bioassayable IGF-I activity in patients with GH-deficiency and healthy subjects.
Kanaley JA; Frystyk J; Møller N; Dall R; Chen JW; Nielsen SC; Christiansen JS; Jørgensen JO; Flyvbjerg A
Growth Horm IGF Res; 2005 Aug; 15(4):283-90. PubMed ID: 16027018
[TBL] [Abstract][Full Text] [Related]
10. Instability of IGF-IGFBP complex as a cause of the different performance of serum and EDTA-plasma after storage: EDTA-plasma is preferable for evaluating bioactive IGF especially in the mouse.
Setoyama T; Miyamoto S; Nikaido M; Muto M; Chiba T
Growth Horm IGF Res; 2015 Oct; 25(5):227-31. PubMed ID: 26144570
[TBL] [Abstract][Full Text] [Related]
11. Bioactive insulin-like growth factors as a possible molecular target for non-islet cell tumor hypoglycemia.
Setoyama T; Miyamoto S; Horimatsu T; Funakoshi T; Nikaido M; Kodama Y; Minamiguchi S; Yamabata T; Muto M; Chiba T
Cancer Biol Ther; 2014; 15(12):1588-92. PubMed ID: 25535894
[TBL] [Abstract][Full Text] [Related]
12. Interstitial fluid contains higher in vitro IGF bioactivity than serum: a study utilizing the suction blister technique.
Espelund U; Søndergaard K; Bjerring P; Flyvbjerg A; Frystyk J
Growth Horm IGF Res; 2012 Dec; 22(6):234-9. PubMed ID: 22939216
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity.
Ricort JM; Binoux M
Endocrinology; 2001 Jan; 142(1):108-13. PubMed ID: 11145572
[TBL] [Abstract][Full Text] [Related]
14. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum.
Jeyaratnaganthan N; Grønbaek H; Holland-Fischer P; Espelund U; Chen JW; Flyvbjerg A; Vilstrup H; Frystyk J
Clin Endocrinol (Oxf); 2010 May; 72(5):625-32. PubMed ID: 19769623
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
Hedman CA; Frystyk J; Lindström T; Oskarsson P; Arnqvist HJ
Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner.
Hermani A; Shukla A; Medunjanin S; Werner H; Mayer D
Cell Signal; 2013 Jun; 25(6):1395-402. PubMed ID: 23499909
[TBL] [Abstract][Full Text] [Related]
17. Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers.
Mishra L; Bass B; Ooi BS; Sidawy A; Korman L
Growth Horm IGF Res; 1998 Dec; 8(6):473-9. PubMed ID: 10985759
[TBL] [Abstract][Full Text] [Related]
18. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors.
Denley A; Carroll JM; Brierley GV; Cosgrove L; Wallace J; Forbes B; Roberts CT
Mol Cell Biol; 2007 May; 27(10):3569-77. PubMed ID: 17325037
[TBL] [Abstract][Full Text] [Related]
19. Kinase Receptor Activation (KIRA): a rapid and accurate alternative to endpoint bioassays.
Sadick MD
Dev Biol Stand; 1999; 97():121-33. PubMed ID: 10463538
[TBL] [Abstract][Full Text] [Related]
20. Targeting the IGF-Axis for Cancer Therapy: Development and Validation of an IGF-Trap as a Potential Drug.
Chen YM; Qi S; Perrino S; Hashimoto M; Brodt P
Cells; 2020 Apr; 9(5):. PubMed ID: 32365498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
